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Neurotransmitter receptor trafﬁcking is fundamentally important for synaptic transmission
and neural network activity. GABAA receptors and inhibitory synapses are vital components
of brain function, yet much of our knowledge regarding receptor mobility and function at
inhibitory synapses is derived indirectly from using recombinant receptors, antibody-tagged
native receptors and pharmacological treatments. Here we describe the use of a set of
research tools that can irreversibly bind to and affect the function of recombinant and
neuronal GABAA receptors following ultraviolet photoactivation. These compounds are based
on the competitive antagonist gabazine and incorporate a variety of photoactive groups. By
using site-directed mutagenesis and ligand-docking studies, they reveal new areas of the
GABA binding site at the interface between receptor b and a subunits. These compounds
enable the selected inactivation of native GABAA receptor populations providing new insight
into the function of inhibitory synapses and extrasynaptic receptors in controlling neuronal
excitation.
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T
he precise coordination of our behaviour requires that we
have adequate temporal control over neuronal excitation.
The responsibility for this control falls largely to
g-aminobutyric acid type A receptors (GABAARs). The timing,
extent and cellular location of synaptic inhibition have a critical
impact on neural network activity and therefore behaviour1–5.
Under normal circumstances, inhibition will be regulated by
endogenous factors, post-translational modiﬁcations and by
plasticity mechanisms. It is therefore unsurprising that
dysfunction to GABAergic inhibition is implicated in numerous
neurological diseases6–8.
The strength (or macroscopic efﬁcacy) of synaptic inhibition
will depend on many factors, not least the number of GABAARs
clustered at the postsynaptic membrane, and the mean
probability of GABA channel opening. Receptor clustering
will be affected by numerous signalling pathways, including
GABAAR phosphorylation9,10; while channel opening will be a
function of the GABA concentration in the synaptic cleft and
the activity of allosteric modulators, such as the neurosteroids11.
Of equal importance for effective synaptic inhibition is the
potential for different GABAAR isoforms with their attendant
differences in physiological and pharmacological properties,
to be targeted to speciﬁc domains (inhibitory synapses) in the
same cell12,13.
To understand how this exquisite targeting of GABAARs to
speciﬁc membrane domains in single cells relates to their impact
on neural activity requires a method to modulate, irreversibly
inactivate and/or to track the movement of such receptors. This
can be partly achieved with ﬁxed tissue by using receptor subtype-
speciﬁc antibodies. Unfortunately this method will not allow any
measure of real-time receptor dynamics14. By contrast, we can
express GABAAR subunits that carry either mutations to critical
structures (for example, ion channel)15, or are tagged with
ﬂuorophore labels16 to reveal real-time dynamics in live cells. The
latter approaches, although extremely useful, nevertheless require
the expression and monitoring of recombinant receptor protein
expressed in native cells, and thus, the behaviour of native
GABAARs can only be ascertained by inference.
Here we take a different approach to enable the direct study of
native GABAARs. This requires the design of novel ligands that
can be attached, and irreversibly bound when appropriately
activated, to native GABAARs. Using available knowledge of the
interfacial GABA binding sites on the GABAAR17, we have
developed a class of ligands that can photoinactivate GABAARs.
These ligands have two major advantages over prior methods:
ﬁrst, we can track native GABAARs in situ without the need for
recombinant receptor expression in neurons, and second, by
choosing a ligand that occludes the GABA binding site, we can
speciﬁcally inactivate populations of GABAARs in particular
areas thereby gaining valuable insight into their function and
trafﬁcking, in addition to revealing the importance of membrane
delimited inhibition.
Results
Designing a photoactivated GABAAR antagonist. We selected
gabazine as the lead structure for synthesizing new photoactive
reagents for several reasons: (i) It is a competitive GABAAR
antagonist that binds to residues in the GABA recognition/
binding site preventing agonist-dependent receptor activation.
This strategy of causing just inhibition was preferred to photo-
active allosteric modulators (often anaesthetics18,19), since these
have multiple effects inducing inhibition and also concurrent
activation and potentiation at GABAA receptors; (ii) gabazine
exhibits partial negative allosteric modulation by inhibiting
GABAAR activation by pentobarbital (barbiturate) and
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Figure 1 | Photoactivated gabazine analogues are antagonists at a1b2c2S GABAA receptors. (a) Structures of GABA, gabazine and the new
gabazine analogues: GZ-i1 (intermediate), GZ-A1 (azide), GZ-B1 and GZ-B2 (benzophenones) and GZ-D1 (diazirine). (b) GABA current inhibition curves
for gabazine and gabazine analogues. The data are normalized (%) to the currents activated by an EC50 (B10mM) for GABA (n¼6–8 cells). Previous
data for GZ-i1 is shown as a dotted line for comparison27. (c) Bar graph of antagonist potencies depicted as pIC50 (left ordinate) and IC50 (right; nM).
The s.e. values only correspond to the pIC50 values. *Po0.05; ***Po0.001; t-test n¼6–8). All data points and bars represent mean values±s.e.m.
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alphaxalone (steroid) from their discrete binding sites on the
receptor20; (iii) gabazine contains an easily identiﬁed ‘GABA
structure’ in the molecule that is unencumbered by other groups,
unlike a similar GABA moiety in bicuculline21, which is another
competitive GABAAR antagonist22,23; and (iv), the phenoxy
group on gabazine presents a chemically convenient site for
attaching photoactivatable groups (Fig. 1a).
Chemistry of gabazine analogues. To maximize the prospects of
obtaining high potency gabazine analogues, we took note of
several key structure–function characteristics of ligands that bind
effectively to the GABA binding site. As the carboxy- and amino-
ends of GABA are important for its engagement at the GABA
binding site24, and the carboxyl side-chain of the GABA moiety
in gabazine is crucial for antagonism25, we avoided making any
modiﬁcations to these parts of the gabazine molecule. We also
noted that the aromatic ring at position 6 on the pyridazine ring
was important in affording gabazine its potency, and should
therefore be retained25–27 (Fig. 1a). Thus, we chose to concentrate
on the phenoxy group as the point of attachment for the
photoactivatable groups, having shown in initial synthetic studies
that the incorporation of a benzyl group led to a further increase
in potency (GZ-i1, Fig. 1a)27.
The following three types of photoactive groups were
incorporated into gabazine: an aryl azide28 (GZ-A1), a
benzophenone29 (GZ-B1) and an aryldiazirine30 (GZ-D1;
Supplementary Fig. 1a). A second truncated benzophenone–
gabazine analogue was also synthesized, where the phenoxy ring
of gabazine was directly replaced by the benzophenone (GZ-B2;
Fig. 1a; Supplementary Fig. 1b). When these photoactive groups
are exposed to ultraviolet (UV) light (wavelengthB300–370 nm)
they respond by forming highly reactive intermediates. In the case
of aryl azides and diazirines, this involves the loss of N2 to afford
a nitrene or carbene, respectively, while the benzophenones form
a photoexcited state that behaves as a diradical. In each case, the
reactive species can then react and covalently attach to nearby
amino-acid residues in the GABA binding site.
Photoactive analogues are high potency inhibitors at
GABAARs. We ﬁrst assessed the gabazine analogues for their
potency in antagonizing a GABA EC50 response using the
synaptic-type recombinant a1b2g2 GABAA receptor expressed in
HEK cells. This would determine if the photoactive groups are
accommodated by the GABA binding site. The synthetic
compound, GZ-i1, is an intermediate between gabazine and
its photoactive analogues. The simple addition of a phenyl
ring increased the potency of gabazine by more than
30-fold27 (Fig. 1b,c), in accord with the 20-fold increase in afﬁnity
(Ki) of GZ-i1 measured using Schild analysis (Fig. 2c,d).
Surprisingly, the relative potencies of the photoactive com-
pounds, GZ-A1 (azide), GZ-B1 (benzophenone) and GZ-D1
(diazirine), were 1.5- to 30-fold higher than that of gabazine, with
the exception of the truncated benzophenone, GZ-B2, which was
equipotent (Fig. 1b,c). While these potency comparisons are
dependent on the GABA concentration used, the afﬁnities of the
photoactive gabazine analogues are not as they are determined
directly using a Schild analysis for competitive antagonism31
(Fig. 2). The antagonist dissociation constants (kB, nM) decreased
in the order: GZ-B2 (318)4Gabazine (300)4GZ-B1 (153)4GZ-
D1 (132)4GZ-A1 (44)4GZ-i1 (13); Fig. 2d). Such a rank order
was unexpected if the molecular volume of the photoactive side-
chain was the major limiting factor for ligand binding. Thus, we
concluded that these large photoactive groups in the phenoxy
position of gabazine are fully accommodated at the GABA
binding site. The increased afﬁnity (lower kB) of the analogues
must therefore result from increased interactions between
gabazine analogues and binding site residues either via
H-bonds, cation–p interactions, or p–p stacking of aromatic rings.
Photoinactivation of recombinant GABAA receptors. The
photoactive capabilities of the azide, benzophenone and diazirine
groups on the gabazine molecule to covalently link to the GABA
binding site were studied using whole-cell recording from HEK
cells expressing a1b2g2S GABAA receptors. The gabazine
analogues, GZ-A1, GZ-B1, GZ-B2 and GZ-D1, were selected, in
conjunction with a photoactivation protocol involving UV
exposure. The intensity and duration of exposure were titrated to
ensure photoactivation of the compounds without perturbing cell
health, ascertained by measuring the membrane leak current and
access resistance. Control whole-cell GABA-activated currents,
recorded before and after applying the photoactivation protocol
(see Methods) in the presence of Krebs alone were unchanged
(101.1±1.8%; mean±sem; n¼ 7; Fig. 3a). This veriﬁed that
under our conditions, UV light exposure did not damage cells or
change GABA potency for a1b2g2 receptors32. Similarly, no
reduction in the GABA-induced current was observed after
applying the photoactivation protocol with gabazine (10 mM;
101.6±3.3%; n¼ 7), indicating that the parent molecule has no
innate photoreactivity, and that 3–5min is sufﬁcient, after UV
exposure, for the antagonist to dissociate from the GABA binding
site (Fig. 3b).
For the azide-linked gabazine analogue, GZ-A1, the GABA-
induced current was reduced irreversibly post-UV by B30% (to
71.3±6.8%; n¼ 7; Fig. 3c,g). For the two benzophenone-linked
gabazine analogues, the post-UV GABA current was irreversibly
reduced by GZ-B1 (to 50.8±1.8%; n¼ 12; Fig. 3d,g), but not by
the truncated version, GZ-B2, lacking one phenyl ring
(98.3±4.2%; n¼ 7; Fig. 3e,g). In comparison, the diazirine-linked
analogue, GZ-D1, irreversibly reduced GABA current by B20%
(to 79.0±4.5%; n¼ 7; Fig. 3f,g). The most efﬁcacious molecule
inducing irreversible block at the GABA binding site was
therefore the ‘extended’ benzophenone–gabazine analogue, GZ-
B1, which was selected for further characterization. The
irreversible nature of the inhibition was evident from extended
recording periods of at least 30min post-UV exposure (Fig. 3h).
The unchanging extent of inhibition and lack of recovery also
re-afﬁrmed that surface GABAA receptors in HEK cells are
not replaced during this period15. Ablation of the agonist
response was routinely achieved with successive cycles of UV
exposure in the presence of 10 mM GZ-B1 (Fig. 3i). To ensure that
some agonist response remained for the measurement of
potencies, we used a single UV exposure cycle in the presence
of GZ-B1.
GZ-B1 has lower potency at a3b3c2 and a4b3d GABAA
receptors. To determine if GZ-B1 exhibited receptor subtype
selectivity, we examined its inhibitory proﬁle for 18 synaptic- and
extrasynaptic-type GABAA receptors, selected because they are
likely to be expressed in the central nervous system33,34. By
varying the highly homologous b-subunits (b1–3) in synaptic-
type a1bxg2 receptors, GZ-B1 potency (IC50) remained constant
(analysis of variance (ANOVA); P¼ 0.26; Fig. 4a,b). Conducting
a similar examination with different a subunits in a1-6b3g2
receptors, GZ-B1 potency was signiﬁcantly reduced at a3b3g2
compared with either a1b3g2 (Po0.001, ANOVA with Tukey–
Kramer post hoc tests) or a6b3g2 (Po0.01; Fig. 4a,b). For the
prospective extrasynaptic-type receptors, GZ-B1 potency
signiﬁcantly varied in the ab and abd subgroups (ANOVA,
Po0.0001), being higher at a6b3 compared with a3b3
(Po0.001) and a4b3 receptors (Po0.01; Fig. 4c,d), and also
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higher at a6b3d compared with a4b3d receptors. Potency was
unaffected by including the d-subunit with a1b2 or a6b3
receptors, but was reduced by its inclusion in a4b3 receptors
(Po0.05). By comparison, potency was unaltered by
incorporating either y or E subunits into a3b3 receptors
(Fig. 4c,d). Comparing the selected synaptic and extrasynaptic
GABAA receptors with a1b3g2 revealed signiﬁcantly lower
potencies for GZ-B1 at a3b3g2 and a4b3d receptors (ANOVA,
Dunnett post hoc test, Fig. 4b,d).
Ligand docking using a GABAA receptor model based on
AChBP. To understand how GZ-B1 binds within the GABA site,
we ﬁrst performed GOLD35 docking simulations of GABA,
gabazine and GZ-B1 with the a1b2g2 GABAA receptor modelled
on the 2Å resolution crystal structure of the unliganded
acetylcholine binding protein (apo-AChBP, PDB ID: 2BYN).
This template was initially selected because loop C, which caps
the binding site when occupied by an agonist36,37, is uncapped,
but not overtly displaced outwards, as observed when a large
competitive antagonist is bound to the same site36. For
antagonists of comparable size to gabazine and GZ-B1, such as
methyllycaconitine, the positioning of loop C in AChBP is
unchanged (PDB: 2BYR)36. The GABA binding site is located at
b–a subunit interfaces surrounded by residues from six binding
loops designated as: A, B, and C from the ‘þ ’ face of the b
subunit and D, E and F from the ‘ ’ face of the a subunit37,38
(Fig. 5a,b). From all the docking results, the most probable
binding mode was selected based on its ranking, its similarity to
GABA interactions with the GABAAR as reported in the literature
and the frequency of its similarity to the other binding modes in
the diverse docking solutions.
Docking GABA, gabazine or GZ-B1 into the GABA site
identiﬁed several charged residues potentially involved in binding
(Fig. 5a,b). Some of these have been previously implicated in
GABA binding39. By docking GABA, we identiﬁed two solutions
(ranked 1 and 2) that predict two different binding modes
whereby the carboxyl group of GABA formed H-bonds with R119
(a1, rank 1) or E155 (b2) and R207 (b2, rank 2) (Supplementary
Fig. 2a). In addition, for the rank 1 solution, H-bonds are also
formed with S156 (b2), G158 (b2), Y159 (b2) and Y205 (b2), and
for the second ranked solution, H-bonds are formed with Y97
(b2) and a cation–p interaction with Y157 (b2). The interacting
residues are spatially spread around the GABA binding site and
hence we predict that GABA potentially binds to the receptor in
two modes. Such interactions have been previously shown to be
involved in GABA binding40,41.
From the gabazine docking, we examined the top 2 ranked
solutions (rank 1 and 2). Rank 1 only had one H-bond interaction
between the carboxyl group of gabazine and R119 (a1). However
for rank 2 the key carboxyl group formed H-bonds with the
receptor residues, R207 (b2) and E155 (b2), and the aromatic ring
was also engaged in a cation-p interaction with R119 (a1)
(Supplementary Fig. 2b). These interactions were also evident
with the top 2 solutions for GABA docking elevating rank 2 as a
potential binding mode compared with the other docking
solutions. In addition, based on the root mean squared deviation
(r.m.s.d.) measure, rank 2 was found to be part of a cluster
of similar binding modes. The cluster contained 24% (12/50) of
the diverse docking solutions, including ranks 3 and 4
(Supplementary Fig. 2c).
For the docking of GZ-B1, we applied a two-stage docking
protocol (Methods). A potential binding mode (Fig. 5d) was ﬁrst
identiﬁed based on the observation that GZ-B1 was interacting
with similar residues (R207 (b2), E155 (b2) and R119 (a1)) to
those identiﬁed in the GABA docking study. Moreover, we
expected GZ-B1 to interact similarly to gabazine, given that
GZ-B1 and gabazine share a core structure. Based on the r.m.s.d.
measure, the observed binding mode was similar in 28% (14/50)
of the diverse docking solutions, including ranks 3 and 5.
(Supplementary Fig. 2d). Next, we explored the binding mode of
GZ-B1 using constraint docking by positioning GZ-B1 in the
binding site enabling residues that could covalently bind to the
photoactivated benzophenone group to be identiﬁed (Methods).
With ‘scaffold-match’ constraints, the activated oxygen of the
benzophenone group was consistently predicted to form an
H-bond with R84 (a1) in our top 3 ranked solutions (rank 1,
Fig. 5e). This ‘region-constraint’ docking method also identiﬁed
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Figure 2 | Afﬁnities of photoactive gabazine analogues. (a) GABA concentration–response curves constructed for a1b2g2 receptors in the absence and
presence of increasing concentrations of the antagonists: gabazine, GZ-A1, GZ-B1 and GZ-D1 (n¼ 5–7). (b) Schild analysis plots for gabazine and each
analogue were derived from a. The linear regression lines are constrained to a slope of 1, indicative of competitive-type of antagonism. Conﬁdence intervals
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(d) Bar graph of kB values for gabazine and all analogues determined by the Schild analysis. All data points and bars represent mean values±s.e.m.
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interactions with either D162 (b2) and/or D163 (b2) (data not
shown).
Ligand docking using a GABAA receptor model based on
GluCl. The predicted binding mode for GZ-B1 obtained from the
ﬁrst stage of docking involved H-bonding with R207 (b2), E155
(b2) and R119 (a1) (Fig. 5f). This binding mode was similar in
32% (16/50) of the diverse docking solutions, including ranks
2, 3 and 4, representing the most populated binding mode
(Supplementary Fig. 2e). Intriguingly, the two-stage docking
protocol predicted a similar binding mode to that observed using
the AChBP template and the scaffold-match constraint. This
identiﬁed an H-bond between the activated oxygen of the
benzophenone group and R84 (a1) (rank 1, Fig. 5g). However,
interactions with D162 (b2) and D163 (b2) were not predicted to
occur either from two-stage docking or from region-constraint
docking.
The docking results predicted that GABA and gabazine are
bound completely within the GABA site behind loop C, whereas
the benzophenone group of GZ-B1 projects up along the b–a
subunit interface and out from under loop C, before re-entering
the interface and terminating near a new cavity between b and a
subunits (Fig. 5d,f). This cavity is predicted to penetrate through
to the external vestibule located above the ion channel. The
intersubunit space around the cavity is considered unimportant
for GABA activation of the receptor, but its volume is such
that competitive antagonists with additional moieties can be
accommodated without impeding binding. Another interesting
observation is that among the unconstrained docking results, the
aromatic ring of GZ-B1 was always orientated towards the
extracellular domain in 68 and 84% of the solutions based on
AChBP and GluCl, respectively. This preferred orientation of
GZ-B1 within the GABA binding site is also supported by the
proposed binding mode (Fig. 5d,f).
Mutating the binding site for GABA, gabazine and GZ-B1. To
examine the predictions from docking simulations that R119
(a1), E155 (b2) and R207 (b2) bind GABA, gabazine and GZ-B1,
we replaced them with similar-sized uncharged glutamines.
Substituting R119 (a1R119Qb2g2) substantially reduced GABA
potency (EC50: 155 mM), while gabazine (IC50: 188 nM) and
GZ-B1 (IC50: 72 nM) potencies were increased by B2-fold,
compared with wild type (Fig. 6a–d; Supplementary Table 1).
Exchanging R207 (a1b2R207Qg2) reduced the potencies for
GABA (EC50: 452mM), gabazine (IC50: 1.71 mM), and GZ-B1
(IC50: 487 nM; Fig. 6a–d; Supplementary Table 1), consistent with
its strong role in the binding of GABA and the competitive
antagonists. For E155Q (a1b2E155Qg2S), a substantial leak
current was evident in the absence of GABA (Supplementary
Table 1) reﬂecting spontaneously open receptors (PB0.7). The
small GABA-induced currents (o100 pA) indicated GABA
potency was B400-fold lower (EC50: 2.6mM) than at wild-type
receptors (Supplementary Table 1). Spontaneous channel
opening42 made conventional assessment of antagonist potency
difﬁcult as the maximum GABA currents were reduced as
expected. Therefore, we examined the inhibition of spontaneous
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channel activity by gabazine and GZ-B1 (relying on their negative
allosteric properties), which revealed very low potencies (IC50s:
4100mM; Supplementary Table 1). Thus, as predicted following
previous studies39,40,42–47, these residues are likely to affect the
binding of the three ligands with potential effects, exempliﬁed by
E155Q, on channel gating.
Residues outside the GABA binding site interact with GZ-B1.
The three charged residues, R84 (a1) and D162/D163 (b2),
identiﬁed as potential binding residues for the benzophenone
group of GZ-B1, were replaced by either glutamine (R84Q) or
asparagine (D162N, D163N). GABA potency was minimally
affected by a1R84Qb2g2 (EC50:17 mM) and a1b2D162, D163Ng2
(EC50:17 mM; Fig. 6a,b; Supplementary Table 1), as expected, due
to their remote location from the GABA binding site. However,
a1R84Q and b2D162N,D163N signiﬁcantly reduced the potency of
GZ-B1 (Fig. 6c,d; Supplementary Table 1), suggesting potential
importance for binding the benzophenone group.
The double mutant, a1R84Qb2R207Qg2, which includes the two
key residues proposed to anchor each end of the GZ-B1 molecule
in the binding site, reduced GZ-B1 potency by a 1,000-fold
(IC50: 182mM), while only halving GABA potency compared with
b2R207Q alone (452mM to 955mM; Supplementary Table 1).
The impact of the b2E155Q mutation on ligand binding is
difﬁcult to interpret as it clearly affects the ability of the ion
channel to remain shut in the absence of agonist. To verify that
the other mutations are only locally affecting the GABA binding
site and not introducing major conformational perturbations into
the receptor, we examined allosteric modulation of the GABAA
receptor. Speciﬁcally, benzodiazepine-induced modulation was
unaffected (Fig. 6e).
Photoactivated GZ-B1 irreversibly binds to a1-R84. The
importance of a1-R84, b2-D162 and b2-D163 for irreversible
binding following photoactivation of GZ-B1 was investigated
using near-saturating concentrations of GZ-B1 before and after
UV. We also examined a1-R119 as a likely candidate to engage in
irreversible bond formation given its close proximity
to the photoactivated oxygen of the benzophenone group in
GZ-B1.
The UV photoactivation protocol did not signiﬁcantly affect
GABA potency or macroscopic efﬁcacy at wild-type receptors
(a1b2g2) in Krebs alone (Supplementary Table 2). For the wild-
type a1b2g2 receptor exposed to UV in the presence of GZ-B1,
the maximum GABA current was reduced to 62±4.2% of control
(n¼ 6) due to irreversible block at the GABA binding site
(Fig. 7a,f). The mutants, a1R119Qb2g2 and a1b2D162N,D163Ng2,
caused only a small or no reduction in the irreversible block of
GZ-B1 when compared with wild-type (to 73±2.6%; n¼ 6; t-test,
P¼ 0.05; and 71±2.6%; n¼ 4; t-test, P¼ 0.1491; respectively;
Fig. 7b,c,f). However, a1R84Qb2g2 caused a substantive reduction
in the level of irreversible block (from 62% to only 84±4.9%;
n¼ 6; t-test, P¼ 0.0067) indicating that a1-R84 is an important
residue for binding of the photoactivated GZ-B1 molecule
(Fig. 7d,f). Finally, we expressed a combined mutant,
a1R84,119Qb2D162,163Ng2, which eliminated the GZ-B1 block
(97±3.4%; n¼ 4; t-test, P¼ 0.0003; Fig. 7e,f). Thus, while
a1-R84 is the most important binding partner for the
photoactivated benzophenone group, a1-R119, b2-D162 and
b2-D163 residues can, to a limited extent, affect the covalent
binding of photoactivated GZ-B1 molecules.
Photoactivated GZ-B1 irreversibly reduces synaptic inhibition.
To assess the ability of photoactivated GZ-B1 to reduce synaptic
inhibition, we recorded from cultured cerebellar granule cells and
monitored whole-cell GABA currents and spontaneous inhibitory
postsynaptic currents (sIPSCs; Fig. 8a). Responses to rapidly
applied GABA (1mM) were depressed to a similar degree, after a
single UV exposure, to those observed for recombinant
a1b2g2 GABAA receptors. No recoveries were observed
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over 40–45min following GZ-B1 photoactivation (Fig. 8b).
Monitoring sIPSCs before and after an identical UV cycle in the
presence of 10 mM GZ-B1 (Fig. 8c) revealed up to a 90% reduc-
tion in synaptic current amplitude, which did not recover during
the recording (B45min; Fig. 8d). This level of inhibition indi-
cates that the synaptic receptors are highly sensitive to inhibition
by photoactivated GZ-B1. The lack of recovery (both whole-cell
GABA currents and sIPSCs) suggests that membrane insertion of
GABAA receptors from intracellular stores must be
relatively slow.
Tracking photolabelled GABAA receptors. The speciﬁc and
irreversible binding of GZ-B1 to neuronal GABAA receptors
provided a means to label such receptors with ﬂuorophores. We
exploited this using a variation of GZ-B1 incorporating a
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Figure 5 | GABA binding site model with docked GZ-B1 molecule. (a) Primary sequence alignment of murine GABAA receptor a1 and b2 subunits. Binding
loops A–C on b2 and D–F on a1 are colour coded. Key residues (grey boxes) involved in reversible binding of GZ-B1 are shown in orange (b2-E155,
b2-R207), residues involved in irreversible binding to photoactivated GZ-B1 are shown in yellow (a1-R84, b2-D162, b2-D163), and a residue involved
in both reversible and irreversible binding is shown in beige (a1-R119). Other residues important for GABA binding are shown in white. (b) Model of the
GABA binding site between b2 (dark grey) and a1 (light grey) subunits based on AChBP (ribbon form). (c) Model of the GABA binding site between
b2 (dark grey) and a1 (light grey) subunits based on GluCl (ribbon form). Loops A–F, a1-R84, 119 and b2-E155, D162, 163 and R207 on b,c are shown using
colour code as in a. (d,e) Predicted binding modes for GZ-B1 based on AChBP using unconstrained (d) and scaffold-match-constrained (e) docking.
(f,g) Predicted binding modes for GZ-B1 based on GluCl using unconstrained (f) and scaffold-match-constrained (g) docking. (d,f insets) Subunit interface
surfaces (b2 is blue; a1 is green) are shown with the benzophenone of GZ-B1 protruding from underneath loop C and settling in a cavity above the
GABA binding site. The unconstrained binding modes for GZ-B1 (d,f) predicted an interaction with R207 (b2), E155 (b2) and R119 (a1). For AChBP,
the scaffold-match-constrained binding mode for GZ-B1 (e) predicted H-bond formation with R84 (a1) and E155 (b2) and a cation–p interaction with
R119 (a1). For GluCl, the scaffold-match-constrained binding mode for GZ-B1 (g) predicted H-bond formation with R84 (a1) and a cation–p interaction with
R119 (a1). The H-bonds are shown as spring representation. Cation–p interactions are depicted as dashed black lines.
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polyethylene glycol linker attached to biotin (Supplementary
Fig. 3a) designed to not interfere with photoactivation of GZ-B1
and its binding to GABAA receptors. This moiety readily reacts
with streptavidin-coated highly ﬂuorescent quantum dots (QD655;
Fig. 9a). By subsequently exposing these molecules to UV light,
we labelled and then tracked the surface mobility of
irreversibly inactivated GABAA receptors on hippocampal
neurons (Supplementary Fig. 3b,c,d; Fig. 9).
GABAA receptors labelled with GZ-B1 exhibited both conﬁned
and mobile trafﬁcking proﬁles in hippocampal neurons as
expected for receptors that are conﬁned at inhibitory synapses
and for those that reside in the extrasynaptic domain (Fig. 9c).
For comparison with GZ-B1, we also labelled separate GABAA
receptors with QDs on a1 subunits via a primary antibody to an
external epitope (Fig. 9b). By tracking receptor mobility labelled
with GZ-B1 or anti-a1 antibody, we determined the diffusion
coefﬁcients (D; Fig. 9d). The median D value after tracking
individual QDs for anti-a1-labelled receptors (0.08; n¼ 788)
(Fig. 9e) was signiﬁcantly reduced for GZ-B1–biotin-labelled
receptors (0.07; Kolmogorov–Smirnov test, Po0.001; n¼ 446
QDs). This probably reﬂects a1 subunit-containing GABAA
receptors predominantly located at synapses, which have lower
D values, compared with GZ-B1–biotin-tagged receptors, which
will include synaptic as well as the faster moving extrasynaptic
GABAA receptor populations. The mean square displacement
plots for GABAA receptors labelled with GZ-B1 (black) and anti-
a1 antibody, revealed no signiﬁcant difference in the conﬁnement
of the receptors. This is likely, as the ensemble of diffusion
coefﬁcients will include a mixed population of various synaptic
and extrasynaptic receptors.
The utility of the GZ-B1–QD label is also emphasized in
studying receptor internalization. Transfected hippocampal
neurons expressing enhanced green ﬂuorescent protein were
labelled with GZ-B1–biotin–streptavidin–QD655 and incubated at
37 C from 0 up to 60min before ﬁxation (Supplementary Fig. 4).
Under these conditions, we followed the trafﬁcking itineraries of
receptors as they internalized into subcellular compartments
(Supplementary Fig. 4; Supplementary Movie 1). Overall, the
GZ-B1–QD complex forms a very useful label for tracking
GABAA receptor movement.
Discussion
Dynamically regulating the number of GABAA receptors at
inhibitory synapses is a vital component of synaptic plasticity
with implications for the long-term control of neuronal
excitability, and for dysfunctional inhibitory transmission during
neuropathological states. Monitoring the trafﬁcking of synaptic
receptors often requires antibodies recognizing an innate epitope,
or a modiﬁed receptor structure to incorporate an epitope that is
either recognized by selective antisera48, or is an inherent
ﬂuorophore49. Further modiﬁcations can enable the receptor to
be coupled to a quantum dot50,51 or carry a mutation that is
recognized by another ligand15. Although useful, such methods
cannot be easily adapted to study native receptors. To address this
problem, we devised a method that irreversibly inactivates native
GABAA receptors, using a new class of photoactivated GABAA
receptor antagonists. These can be used to investigate inhibition
in various membrane domains and by linking the photoactivated
antagonists to ﬂuorophores, we can simultaneously investigate
both receptor function and receptor trafﬁcking.
Gabazine is an ideal lead compound due to its high afﬁnity for
the GABA binding site, its suitability for chemical synthesis, and
the ease by which structural modiﬁcations can be made25,26. By
attaching photoreactive groups to the phenoxy-end of gabazine,
away from the GABA backbone, we found that these analogues
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retained or even increased their afﬁnity for the GABA binding
site. This feature was also noted by attaching a benzyl group in a
similar position27, indicating that these molecules are capable of
extensive binding site interactions in the ‘vaulted’ space of the
interfacial GABA binding site revealed by our homology models
of the GABAA receptor. Previous studies of the GABA partial
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agonist, 4-PIOL, have also showed the cavernous nature of the
GABA binding site, by accommodating large aromatic analogues
with increased apparent binding afﬁnity52. Possibly the
hydrophobic nature of 4-PIOL53 and our gabazine analogues,
may facilitate hydrophobic interactions (for example, p–p
stacking) in the GABA binding site, which is lined with a
number of aromatic side-chains.
The extended benzophenone analogue, GZ-B1, proved the
most effective at irreversibly blocking a1b2g2 GABAA receptors
following UV photoactivation, with near-saturating
concentrations blocking B50% of GABAA receptors in an
irreversible manner after only one cycle of UV. Although
submaximal, this is more than sufﬁcient for functional and
trafﬁcking studies of GABAA receptors15. A similar level of
inhibition was also reported for the photoactive glutamate
receptor inhibitor, ANQX, on AMPA receptors54. However, for
experiments that demand complete inhibition of GABA currents,
several cycles of UV exposure can achieve this; although synaptic
GABA currents can be virtually abolished by very few cycles of
UV activation of GZ-B1. The reason why the block becomes more
effective with successive UV exposure, most likely relates to the
photochemical properties of the benzophenone group, which,
unlike the azide and diazirine groups, does not lose N2 upon
photoexcitation and thus can readily revert back to its ground
state. This feature is advantageous since it allows the
benzophenone group to have repeated attempts at covalent
binding during successive periods of photoactivation.
The GABA concentration–response curves with GZ-B1 after
photoactivation revealed a non-competitive depression compared
with the competitive inhibition noted with reversible binding of
GZ-B1 in the absence of UV. This is the expected behaviour of an
irreversible antagonist at the agonist binding site, whereupon the
GABA EC50 remains largely unaffected.
Once Cys-loop receptor agonists, such as GABA, are
accommodated at their binding site, loop C is proposed to close,
capping the binding site36,37,55, whereas no movement of loop C
is observed with larger ligands of comparable size to gabazine and
GZ-B1 (ref. 36). For the GZ-B1 molecule, computational docking
analysis revealed that the benzophenone group extends along the
b–a subunit interface to a region outside the recognized GABA
binding site. Interestingly, aligning the primary sequences of a
and b subunits along this part of the interface identiﬁed a lack of
homogeneity for the a-subunits (Supplementary Fig. 5), which
could underlie the slightly different potencies of GZ-B1 at some
GABAA receptors. However, the activity of GZ-B1 at both
synaptic- and extrasynaptic-type GABAA receptors suggests it can
be considered as a broad spectrum photoactive antagonist.
The accuracy of our computational docking models for GABA,
gabazine and GZ-B1 was afﬁrmed by identifying a1-R119,
b2-E155 and b2-R207 as key interacting residues in the GABA
site, which have been previously reported39,40,42–47. This enabled
the positioning of GZ-B1 within the binding site, and by further
docking studies, the identiﬁcation of new residues, a1-R84,
b2-D162, b2-D163, and potentially a1-R119, as interactors with
the benzophenone group.
While mutating these residues did not affect GABA binding,
they were important for the reversible binding of GZ-B1, since a
combined mutation, a1-R84Q and b2-R207Q caused a 41,000-
fold loss of potency. We identiﬁed a1-R84 as the most important
binding partner for the UV-activated GZ-B1 molecule, over
b2-D162, b2-D163 and a1-R119. This suggests that GZ-B1 is
optimally irreversibly bound in just one conformation at the
binding site, with suboptimal binding conformations occasionally
adopted. However, we should emphasize that docking solutions
represent energy-minimized snapshots of the most prevalent
three-dimensional (3D) orientations of the bound ligand. Never-
theless, the bound ligand, as well as the amino-acid side-chains at
the binding site, will be constantly undergoing Brownian motion-
like movement during covalent binding of GZ-B1. Thus, while the
photoactivated benzophenone may, most commonly, associate
with a1-R84, it could, at different times, associate with a1-R119,
b2-D162 or b2-D163. These residues may play key roles in the
energy-minimized positioning of GZ-B1 at the binding site, that
is, by controlling the efﬁciency of the covalent attachment.
Applying GZ-B1 to cerebellar granule cells indicated that
synaptic GABAA receptors are very susceptible to inhibition and
that this inhibition was irreversible over the time course of our
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Figure 9 | Mobility of QD-labelled GABAA receptors on hippocampal
neurons. (a,b) Schematics and trajectories for individual QDs photo-linked
to GABAA receptors via GZ-B1–biotin (a) and for GABAA a1 subunits
tagged with QDs via a primary antibody against a1 and a secondary
antibody containing biotin and QD655–streptavidin (b). (c) Examples of
trajectories from a of mobile (M) and conﬁned (C) QDs/receptors.
Conﬁned QDs/receptors are most likely anchored at inhibitory synapses,
whereas the more mobile QDs/receptors are thought to reside in the
extrasynaptic domains. Trajectories were analysed using the ImageJ plug-in,
SpotTracker 2D/3D and MatLab. Scale bars, 1 mm. (d) Diffusion coefﬁcients
of GABAA receptors labelled with GZ-B1–biotin or with antibodies against
a1 subunits. (e) Distribution of diffusion coefﬁcients shown as a box-and-
whisker plot (median, 25–75% interquartile range, whisker¼ 5–95%) for
GABAA receptors tagged with GZ-B1 (n¼446) or with anti-a1 antibodies
(n¼ 788; ***Po0.001, Kolmogorov–Smirnov test). (f) Mean square
displacement (MSD) versus time plot of GABAA receptors labelled with
GZ-B1 and anti-a1 antibody. There was no signiﬁcant difference in the
conﬁnement of the receptors. All data points and bars represent mean
values±s.e.m.
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recordings (usually 440min). The level of inhibition was higher
than that for whole-cell GABA currents. However, this does not
involve changes to the afﬁnity of the antagonist for the GABAA
receptors. By simulating synaptic and whole-cell GABA currents,
the brief GABA concentration transient (B1ms) and synaptic
receptor occupancy expected at inhibitory synapses resulted in a
higher level of block compared with that for longer whole-cell
applications (B4 s) and correspondingly longer duration receptor
occupancies.
In conclusion, by generating a new photoactivated gabazine
analogue, GZ-B1, we can use UV photoactivation to irreversibly
inactivate native GABAA receptors both within and outside
inhibitory synapses in addition to studying their trafﬁcking
without the need to having to use expression-tagged recombinant
receptors or antibody-based labelling procedures. By determining
where the photoactivated molecule is likely to bind, we have also
mapped residues in a new region of the interface between b and a
subunits just above the GABA binding site.
Methods
cDNA constructs. Murine a1 and b2 subunits and all point mutants were cloned
into the plasmid pRK5, and veriﬁed by full-insert sequencing.
Cell culture and expression of recombinant GABAA receptors. HEK cells
(ATCC, UK) were maintained in Dulbecco’s Modiﬁed Eagle’s Medium supple-
mented with 10% v/v fetal calf serum, 200mM L-glutamine and 100Uml 1
of penicillin/Streptomycin at 37 C (95% air/5% CO2). Cells were plated onto
poly-L-lysine coverslips and transfected with cDNAs encoding enhanced green
ﬂuorescent protein and murine a1-6, b1-3, g2S, d, e and/or y GABAA receptor
subunits using a calcium–phosphate method. Cells were used for electrophysiology
experiments after 16–48 h (ref. 34).
Dissociated neuronal cultures were prepared from (E18-P4) Sprague–Dawley
rats in accordance with UK Home Ofﬁce regulations. Tissue blocks were incubated
in trypsin for 10min (0.1% w/v), washed in HBSS and then triturated in DNase
(0.05% w/v in 12mM MgSO4). Cells were plated on poly-L-ornithine-coated glass
coverslips and cerebellar neurons were maintained in Basal Medium Eagle
supplemented with 0.5% (w/v) glucose, 5mg l 1 insulin, 5mg l 1 transferrin,
5mg l 1 selenium, 20Uml 1 penicillin G and 20 mgml 1 streptomycin, 0.2mM
glutamine, 1.2mM NaCl and 5% (v/v) fetal calf serum. Hippocampal neurons were
maintained in Neurobasal A supplemented with 1% v/v B-27, 50Uml 1
penicillin-G and 50 mgml 1 streptomycin, 0.5% v/v Glutamax, and 35mM glucose
before transfection using a calcium phosphate-based method.
Chemistry of gabazine analogues. To synthesize the photoreactive analogues,
we developed a highly concise general strategy (Supplementary Fig. 1a).
Suzuki–Miyaura coupling of 4-hydroxybenzeneboronic acid (referred to as ‘1’ in
Supplementary Fig. 1a) with 3-amino-6-chloropyridazine afforded a biaryl building
block (2)27, which could then be reacted with the appropriate benzyl bromide to
attach the photoactivatable groups. Finally, N-alkylation and mild deprotection of
the allyl group afforded the products (3; either GZ-A1,-B1 or -D1) in just 4 steps
and with good overall yields. The only exception to this strategy involved the
synthesis of the truncated analogue GZ-B2, in which the boronic acid of the
benzophenone was used directly, resulting in just a 3-step synthesis (Supplemen-
tary Fig. 1b; Supplementary Table 3, Supplementary Information—Chemistry).
Electrophysiology and UV photoactivation. Whole-cell currents and sIPSCs
were recorded from cells voltage clamped at  60mV using an Axopatch 200B
ampliﬁer (Molecular Devices). Currents were ﬁltered at 5 kHz ( 3dB, 8 pole
Bessel, 48 dB per octave) and digitized at 50 kHz via a Digidata 1320A (Molecular
Devices) and recorded direct to a hard drive. Patch pipettes with a resistance of
either 3–4MO (HEK cells) or 8–9MO (cerebellar granule cells) were ﬁlled with an
intracellular solution containing (mM): 140 CsCl, 2 NaCl, 2 MgCl2, 5 EGTA, 10
HEPES, 0.5 CaCl2, 2 Na-ATP, 0.5 Na-GTP and 2 QX-314; pH 7 (adjusted with 1M
caesium hydroxide). Cells were continuously perfused with Krebs solution con-
taining (mM): 140 NaCl, 4.7 KCl, 1.2 MgCl2, 2.52 CaCl2, 11 Glucose and 5 HEPES;
pH 7.4 (adjusted with 1M NaOH). In cerebellar granule cell experiments, the
Krebs solution contained CNQX (10 mM) and AP5 (20 mM) to inhibit excitatory
synaptic currents dependent on glutamate receptors. Drugs were applied to cells
using a U-tube application system56.
Photoactivation was performed using a Rapp OptoElectronic JML-C2, with a
band-pass ﬁlter of 240–400 nm and an optic ﬁbre located in the bath 1–2mm from
the recorded cell. A single cycle of an optimized photoactivation protocol consisted
of 10 ﬂashes (2-s interval), capacitance 2 setting (C2) at 150V. After UV exposure
in the presence of the antagonist, the cell was left to rest for 3–5min while washing
with recording solution, to ensure that only covalently bound antagonist would
remain in the binding site.
Analysis of whole-cell current data. GABA concentration–response relation-
ships were analysed by normalizing GABA currents to the response induced by a
maximal, saturating GABA concentration (Imax) and subsequently ﬁtting with the
Hill equation:
I=Imax¼ ð1=1þðEC50=½AÞnÞ½  ð1Þ
where EC50 represents the concentration of the agonist ([A]) inducing 50% of the
maximal current evoked by a saturating concentration of the agonist and n
represents the Hill coefﬁcient.
Antagonists were evaluated for their potency by constructing inhibition–
concentration relationship curves and ﬁtting the data using:
I=Imax¼ 1 1=1þ IC50=½Bð ÞnÞ½  ð2Þ
where the IC50 is the antagonist concentration ([B]) causing half-maximal
inhibition of the GABA (EC50)-induced response. When complete inhibition was
not attained, the above equation was modiﬁed to:
I=Imax¼Imin þ Imax  Iminð Þ 1 1=1þ IC50=½Bð Þn½ Þð  ð3Þ
where Imin represents the residual GABA current remaining with a saturating
concentration of antagonist, and Imax represents the control peak GABA-activated
current.
The IC50 values obtained from individual experiments were converted to pIC50
values (¼  Log (IC50). Mean pIC50 values±s.e.m. of at least four experiments
were subject to statistical analyses (ANOVA and Student’s t-test). Potency
histograms have two y axes for mean pIC50 values±s.e.m., and the IC50 transform
(note: error bars refer only to the pIC50).
The competitive antagonism caused by gabazine and its analogues was analysed
according to the Schild method31. Full GABA concentration–response curves were
obtained in control Krebs in each HEK cell and then one or more curves were
established in up to four concentrations of gabazine or one of its analogues. The
curves were tested for parallelity and the dose ratios for GABA were calculated
from the respective GABA EC50s. The mean dose ratios for each antagonist
concentration (B) allowed the dissociation constant (kB) to be determined using the
transformed Schild equation:
Log DR 1ð Þ¼ logB logkB ð4Þ
The slope of the Schild plot (log (DR 1) versus log [B]) was tested to ensure its
slope did not deviate signiﬁcantly from unity. The slopes were then constrained to
1 and the intercept on the abscissa (‘dose ratio—1’) was used to ascertain the pA2
(¼  log kB).
The level of spontaneous activity observed with mutant GABAA receptors
containing the b2E155Q mutation was determined as, the maximal inhibition of
channel activity observed in the presence of 1mM picrotoxin (IPTXmax), divided
by the total range of channel activity (IPTXmaxþ IGABAmax) (ref. 57).
Homology modelling and computational docking. Murine a1, b2, g2 subunits
were aligned to the subunit sequence of AChBP and GluCl using the T-COFFEE
server58 with manual adjustment. Based on the alignment, two 3D homology
models of the a1b2g2 GABAA receptor were built with MODELLER59 using the
crystal structures of AChBP (PDB ID: 2BYN) at 2.02 Å resolution and of GluCl
(PDB ID: 3RHW) at 3.26 Å resolution. The GABAA receptor a1 subunit exhibits
22% and 31% sequence identity with those of AChBP and GluCl, respectively. In
comparison with AChBP and GluCl, the GABAA receptor b2 subunit shares 22%
and 36% sequence identity.
Initially, our docking studies were performed on the GABAA receptor homology
model derived from AChBP. First, GABA, gabazine and GZ-B1 were docked into
the GABA binding site of the homology model. The binding site cavity was deﬁned
such that all the receptor residues deﬁned within a sphere of 10Å radius from the
a-carbon of Y157 (b2) were included. Hermes version 1.4.1 interface and GOLD
version 5.0.1 (ref. 35) were used to initiate docking. The genetic algorithm settings
in GOLD were automatically optimized with maximum search efﬁciency. During
the ﬁrst stage, all the ligands were docked into the binding site and were kept fully
ﬂexible during docking. Ten residues within the binding cavity were selected and
their side-chains were allowed full ﬂexibility during docking: F64 (a1), R66 (a1),
R119 (a1), Y97 (b2), F98 (b2), E155 (b2), Y157 (b2), Y159 (b2), F200 (b2), Y205
(b2) and R207 (b2). For each of the ligands, 50 diverse docking solutions were
generated using the GoldScore scoring function with default parameters. From our
homology models, we identiﬁed a new cavity at the b–a subunit interface (located
higher up than the GABA binding site), which could feasibly accommodate large
ligands. To further explore the potential binding residues found in the new cavity,
we performed a second stage of docking only for the GZ-B1 case, using GOLD with
the ‘scaffold-match constraint’ (starting from the selected binding mode obtained
from the ﬁrst stage of docking without any constraints). The scaffold-match
constraint was used to maintain a fragment at an exact speciﬁed position in the
binding site with the geometry of this fragment remaining unaltered during
docking. All the atoms in GZ-B1 molecule, except the benzophenone group, were
retained as a scaffold.
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To investigate the new binding cavity, we performed further docking using a
separate ‘region constraint’. This was used to bias the docking solutions towards a
particular region of the binding site, constraining speciﬁc ligand atoms in this
region. For this constraint, the centroid of the residues deﬁning the oriﬁce of the
new cavity (R84 (a1), L85 (a1), N87 (a1), F31 (b2), D162 (b2) and D163 (b2)) was
calculated with Chimera60 and the binding site region was deﬁned within a sphere
of 5Å radius around this centroid. All the benzophenone atoms of GZ-B1 were
constrained to occupy the new binding site region. The receptor residues in and
around the new cavity (R84 (a1), L85 (a1), N87 (a1), R119 (a1), F31 (b2), Y159
(b2), T160 (b2), D162 (b2), D163 (b2) and Y205 (b2)) were allowed full ﬂexibility
during the docking runs.
All the docking studies on GZ-B1 described above (two-stage docking and
region-constraint docking) were also applied to the GABAA receptor homology
model derived from GluCl. For the two-stage docking, we included an ‘H-bond
constraint’ in addition to a scaffold-match constraint. The new constraint was
added to promote H-bond interaction between the acceptor oxygen atom of the
benzophenone in GZ-B1 and the donor nitrogen atoms of side-chain of R84 found
in the newly identiﬁed cavity.
For analysing the results, all the H-bond interactions were identiﬁed using
GOLD. We also analysed cation–p interactions, which are considered to be
important for drug–receptor binding and are energetically comparable to H-bond
interactions61. If the distance between the cation and the centroid of the p system is
within 6Å, and the angle between the line joining the cation, and that the centroid
and the normal to the aromatic plane at the centroid is between 0 and 90, we
accepted this as a cation–p interaction62. The r.m.s.d. was used as a measure to
compare different binding modes. For r.m.s.d. calculation, we only used the
scaffold atoms of gabazine and GZ-B1 (those forming the rings and connecting
them). Two binding modes with r.m.s.d. less than or equal to 2.5 Å were considered
to be similar.
Tracking GABA receptor mobility. The mobilities of GABAA receptors in
cultured hippocampal neurons were tracked using QDs photo-linked to GABAA
receptors via GZ-B1–biotin (see legend to Supplementary Fig. 4). Cells were
treated with 0.5mM GZ-B1–biotin (previously incubated for 3min with 25 pM
QD655–streptavidin; Life Technologies) and either not exposed (control) or
UV exposed (40 s) followed by washing of cells in Krebs solution.
Mobilities were also studied using GABAA a1 subunits tagged with QDs via a
primary antibody against a1 (gift from Jean-Marc Fritschy, Zurich; incubation in
1 mgml 1 for 2min) and a secondary antibody containing biotin (Millipore;
incubation in 5 mgml 1 for 2min) and QD655–streptavidin (25 pM; 1min
incubation). Trajectories were analysed using the ImageJ plug-in, SpotTracker
2D/3D and MatLab.
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